Breast Cancer

FDA Approves Femara as First-Line Therapy for Advanced Cancer

Published in Women's Health Weekly, February 1st, 2001

The U.S. Food and Drug Administration (FDA) approved an indication for Femara (letrozole) as a first-line treatment for postmenopausal women with hormone receptor positive or hormone receptor unknown, advanced or metastatic breast cancer.

Femara, an aromatase inhibitor, was approved for treatment of advanced breast cancer in 1997 in women whose cancer had not responded to antiestrogen drugs. Femara was shown to be more effective than tamoxifen in a randomized, double-blinded, multinational trial of more than 900 postmenopausal women, with locally advanced or metastatic breast cancer not amenable to treatment with surgery or radiation.

In the study,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2001-02-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry